Merkel cell carcinoma (MCC) is a rare aggressive cutaneous malignancy of the elderly and immunocompromised populations. The clinical presentation of MCC is nonspecific, with the majority of cases presenting as localized skin involvement. Histologically and immunophenotypically, MCC is defined by both neuroendocrine and epithelial differentiation. Recently, the Merkel cell polyomavirus has been implicated in the pathogenesis of MCC. In addition, there have been numerous studies evaluating the histologic and immunohistochemical characteristics of MCC as they relate to diagnosis and prognosis. The purpose of this paper is to review the most salient and clinically relevant updates in the pathogenesis and histologic features of MCC. Specific attention is given to the clinical and histologic predictors of prognosis, staging, and the controversies concerning sentinel lymph node biopsy and therapy.
(Adv Anat Pathol 2010;17:155-161) NOMENCLATURE From 1966 to 1970, Dr Cyril Toker noted a series of elderly patients presenting with cutaneous neoplasms with distinctive histologic features. Several of these cases were diagnosed as metastatic carcinomas despite local recurrence and lack of a primary tumor elsewhere in the body. At the time, Dr Toker's intent was to report this undescribed primary cutaneous neoplasm, that could be mistaken for a metastatic carcinoma. These tumors were composed of anastomosing trabeculae ranging in size from slender to broad and confluent, consisting of uniform cells with scant cytoplasm and ill-defined cell boundaries. On the basis of the aforementioned histomorphologic features, these tumors were given the designation ''Trabecular'' carcinoma. 1 The name ''Trabecular'' carcinoma emphasized the histologic nueroendocrine features characteristic of these neoplasms. Arguments were made against this designation, because all the tumors did not have a trabecular pattern of growth, and the latter pattern of growth could be seen in other neoplasms of nonneuroendocrine derivation. 2 On the basis of the description of cytoplasmic neurosecretory granules, further showing neuroendocrine differentiation, the argument was made to name this tumor after the possible cell of origin; the Merkel cell. 3 Currently, the most commonly accepted designations include Merkel cell carcinoma (MCC) and primary cutaneous neuroendocrine carcinoma.
CELL OF ORIGIN
In one of the initial manuscripts by Dr Toker pertaining to MCC, he described the exocrine (sudoriferous) and endocrine (neurosecretory) features of this tumor and raised the question of a potential origin from a mature sudoriferous cell, Merkel cell, or a pluripotential precursor. He answered this question with ''We do not know the answer and are never likely to know it.'' 4 Today, there is ongoing research and debate concerning the origin of MCC. Merkel cells were initially described by Fredrick Merkel in 1875 and are thought to be slowacting mechanoreceptors in the basal layer of the epidermis sensitive to touch and hair movement. Merkel cells migrate from the neural crest to the skin and are of neuroendocrine origin. 5 In the skin, these specialized mechanoreceptor cells express both neuronal and epithelial markers, thus a potential cell of origin for MCC. MCC shares similar immunophenotypic features with normal Merkel cells including positivity for cytokeratin (CK) 20, Neuronspecific enolase, and chromogranin. 6 The presence of membrane-bound granules with dense cores in MCC, resembling the secretory granules of Merkel cells, supports a derivation from a neural crest mechanoreceptor cell. 3 Histologically, MCC can show intraepidermal epidermotropic spread with an intraepidermal component more extensive than the dermal component, 7 or even lack a dermal component (MCC in situ). 8 These patterns of growth are uncommon, accounting for 3.2% to 9.1% of reported cases. [9] [10] [11] [12] In such cases, the argument can be made that these tumors may arise from intraepidermal Merkel cells. The vast majority of MCC present as dermal-based tumors, in which case, it is postulated that these tumors arise from Merkel cells that reside in the dermis. Of interest, MCC tumor cells have also been reported involving adnexal epithelium, 13 trichilemmal cysts, 14 and epidermal inclusion cysts. 15 Currently, it is thought that MCC is probably not derived from Merkel cells, rather from a primitive totipotential stem cell with the ability to differentiate along divergent histologic phenotypes. There are numerous reports in the literature describing MCC associated with squamous, 16 squamous and sarcomatous differentiation, 17 melanocytic tumors, 18 eccrine, 19 leiomyosarcomatous, 20 rhabdomyoblastic, 21 and fibrosarcomatous differentiation. 22 These reports support the theory that MCC may arise from a primitive epidermal stem cell with the capacity to differentiate along different cell lines.
CLINICAL PRESENTATION
MCC generally present as a red/pink or violaceous firm nodule, without ulceration, and often with overlying telangiectasias. The aforementioned clinical presentation is not specific for MCC, therefore, emphasis is placed on the fact that the diagnosis is rarely made clinically. The nondescript clinical features of MCC allow this entity to be mistaken for angiosarcoma, basal cell carcinoma, cutaneous lymphoma, squamous cell carcinoma, and melanoma.
In the literature there is a general consensus that MCC is a tumor primarily of the elderly population. The mean age of diagnosis is 76 years for women and 74 years for men, with only 4% of patients with MCC 49 years or younger. In addition, the majority of patients are white (94.9%) with a male predominance (1.6:1). 23 MCC also affects the immunosuppressed, including those with human immunodeficiency virus, chronic lymphocytic leukemia (CLL), and solid organ transplant. It is estimated that 7.8% of patients with MCC are immunosuppressed. 24 In a study of 41 organ recipients with MCC, 29% of patients were younger than 50 years of age and 68% had nodal disease at presentation, showing an early and potentially more aggressive presentation compared with the immunocompetent. 25 In contrast, a large cohort study of 195 patients diagnosed with MCC showed a comparable mean age of presentation between the immunosuppressed and immunocompetent; 65 versus 67 years, respectively. These contradicting findings may be explained by a patient population bias (the proportion of patients presenting with CLL vs. those with human immunodeficiency virus and organ transplant) as CLL is a disease of the elderly. Of note, the latter study also observed more advanced disease at the time of presentation in the immunosuppressed compared with the immunocompetent patients with MCC. 24 In a study of 195 patients by Heath et al, 24 a majority of primary lesions were 1 to 2 cm in size (43.3%), with 88% of patients reporting no symptoms at the time of presentation. Additional clinical features included rapid enlargement, rare ulceration, and a location in areas of chronic sun exposure. The most common primary sites included the head and neck (29%), the lower limbs (24%), upper extremities (21%), and 19% of lesions presented in minimally sun exposed areas (ie, the buttock). The acronym ''AEIOU'' was suggested to emphasize the 5 most common clinical features of MCC: Asymptomatic, Expanding rapidly (<3 mo), Immunosuppression, Older than age 50, location on a UV-exposed site.
Further emphasizing the nonspecific clinical features of MCC, in a group of 106 patients diagnosed with primary MCC, the clinical impression was benign in 56% of cases. The most common presumptive diagnoses included: cyst/acneiform lesion (32%), lipoma (6%), fibroma (4%), and vascular lesion (4%). In the same study, 36% of the cases were submitted with a clinical impression of malignancy including: nonmelanoma skin cancer (19%), lymphoma (6%), metastatic carcinoma (2%), and sarcoma (2%). Of note, the correct clinical diagnosis of MCC was only made presumptively in 2 cases (1%). 24 These findings highlight the importance of maintaining a high clinical suspicion for this malignancy in the appropriate clinical context to avoid delays in diagnosis and management.
PATHOGENESIS
Arguably, one of the most important recent advances in the pathogenesis of MCC involves the discovery of the Merkel cell polyomavirus (MCV). The initial report used digital transcriptone subtraction to identify foreign viral transcripts with human high-thoroughput clonal DNA (cDNA) sequencing data. Two cDNA libraries were made from 4 MCC tumor samples; 1 cDNA library was made from mRNA from a single tumor and the second cDNA library was made by pooling the mRNA from 3 tumors to increase the likelihood of detecting a rare viral sequence. After identifying the novel MCV sequence, 8 of 10 cases (80%) of MCC were shown to be positive for MCV sequences by polymerase chain reaction (PCR). Furthermore, in 6 of the 8 cases positive for MCV sequences, the viral DNA was integrated within the tumor genome in a clonal pattern. These findings suggest that the MCV infection and integration preceded tumoral clonal expansion. 26 Further supporting the findings of Feng et al, 15 (88%) of 17 frozen section MCC tumor samples showed MCV DNA by quantitative PCR. Of the 17 samples, 15 cases had sufficient archival tissue to allow immunohistochemical (IHC) evaluation of CM2B4, a monoclonal antibody directed against an antigenic epitope on the MCV T antigen. Ten (67%) of the tumors showed IHC expression of CM2B4, and all cases positive for CM2B4 also showed MCV by PCR. In addition, a microarray of 36 MCC, 7 combined cutaneous squamous and neuroendocrine carcinomas, and 26 small cell carcinomas of the lung (SCCL) were evaluated for the IHC expression of CM2B4. Of the 36 MCC evaluated, 27 (75%) were immunoreactive for CM2B4, whereas none of the combined cutaneous squamous and neuroendocrine carcinomas or SCCL were positive. 27 On the basis of these findings, it is possible that neuroendocrine carcinomas with an associated squamous cell carcinoma (SCC) component may arise in a MCV independent manner; begging the question: ''Should these tumors be classified as MCC.'' In another study, 33 cases of MCC, 12 seborrheic keratosis, 11 basal cell carcinomas, and 10 lentigo maligna melanomas were analyzed for the presence of the MCV sequence. Twenty-one (64%) of MCC and 2 seborrheic keratosis lesions showed the MCV sequence. 28 Several findings argue a role for MCV in the pathogenesis of at least a subset of MCC. Such findings include the detection of MCV DNA in the majority of MCC cases, viral integration as an early event before tumor clonal expansion, expression of the large T antigen transcript, and the occurrence of MCC in immunosuppressed patients. Alternatively, not all cases of MCC show MCV infection, and MCV infection is not exclusive to MCC. MCV virus has been detected in 16% (4 of 25) normal control skin tissues and 8% (5 of 59) control tissues from various body sites. 26 To date, the causal role of MCV in the pathogenesis of MCC is yet to explain the marked predilection of this tumor to develop in white patients and in areas of chronic sun exposure.
Traditionally, chronic sun exposure has been implicated in the tumorigenesis of MCC. The majority of MCC present in areas of chronic sun exposure (ie, head, neck, and extremities), and in white patients older than 50 years of age. These features support a possible etiologic role for ultraviolet (UV) radiation in the development of MCC. The hallmark of UVB damage is the cytosine (C) to thymidine (T) DNA base transitions and the CC to TT double base substitutions in the p53 gene. Using comparative genomic hybridization, UVB-specific mutations in the p53 gene have been shown in MCC. In addition, shared chromosomal imbalances between MCC and SCC suggest the possibility of UVA-induced oxidative damage. 29 Interestingly, there is a reported increased incidence of MCC in psoriasis patients receiving UVA phototherapy. 30 Despite these associations, not all cases of MCC occur in sun exposed areas nor do all MCC show UV-specific mutations. Therefore, the pathogenesis of MCC is yet to be completely elucidated and will most likely prove to be multifactorial.
HISTOLOGY
The majority of MCC are dermal-based tumors which at low-power magnification places the tumor in the small blue-cell tumor classification. At low-power the differential diagnosis for MCC includes metastatic small cell carcinoma, lymphoma, Ewing sarcoma, neuroblastoma, rhabdomyosarcoma, melanoma, and basal cell carcinoma. Architecturally, MCC shows a variety of histologic patterns including organoid, trabecular, ribbon-like, and diffuse ( Fig. 1) . Cytologically, the tumor cells are ovoid with scanty cytoplasm, vesicular nuclei with a dispersed ''salt and pepper'' chromatin pattern, and small or absent nucleoli. Other features characteristic of MCC include areas of necrosis, frequent apoptotic bodies, and a variable lymphocytic infiltrate (Fig. 2) .
Although the majority of MCC are dermal-based tumors with extension into the subcutaneous tissues, some MCC may present with pagetoid intraepidermal pattern ( Figs. 3, 4 ). In the literature, the reported rate of epidermal involvement by MCC is less than 10%. [9] [10] [11] [12] In the majority of cases, the epidermal involvement is usually a minor component, but there are reports in which the epidermal component of tumor exceeds the dermal portion. 7 In addition, there are rare case reports of intraepidermal MCC with no dermal component. 8 In cases of epidermotropic MCC, the differential diagnosis includes other entities which can present with a pagetoid pattern: Paget disease, Bowen disease, cutaneous T-cell lymphoma, melanoma, and sebaceous carcinoma.
As described above, the majority of MCC are histologically pure tumors composed of a homogenous cell population. Rarely MCC are composed of a nonneuroendocrine component, the most common being SCC 16 (Fig. 5 ). Other combined tumors include MCC with eccrine tumors, 19 cysts, 14, 15 melanocytic component, 18 leiomyosarcoma, 20 rhabdomyosarcoma, 21 and fibrosarcoma. 22 Immunohistochemistry plays an integral role in the diagnosis of MCC because of its nonspecific clinical presentation and extensive list of differential diagnoses. MCC is defined by both neuroendocrine and epithelial differentiation. Epithelial markers positive in MCC include epithelial membrane antigen, CAM5.2, AE1/AE3, and CK20. Positive neuroendocrine markers in MCC include: Neuron-specific enolase, chromogranin, synaptophysin, and neural cell adhesion molecule (NCAM/CD56). The majority of MCC show characteristic perinuclear punctate CK20 expression and are negative for CK7. In a review of 32 and present in 23% of MCC. 33 Of note, there are documented cases of CK20+/ CK7+, CK20+/CK7 À, CK20 À/CK7 À, and most recently CK20 À/CK7+ subset of MCC. 34 Along with CK20 and CK7, thyroid transcription factor-1 (TTF-1) has been shown to be useful in distinguishing MCC from metastatic small cell carcinoma of the lung. Evaluating TTF-1 expression in MCC, 85% (28/33) of SCCL were positive for TTF-1 and 0% (0/21) MCC were positive for TTF-1. 35 Recently, mammalian achaete-scute homolog-1(MASH1) IHC expression was evaluated in SCCL and MCC, and shown to be more sensitive than TTF-1. MASH1 is a transcription factor essential for neuroendocrine cell differentiation, and has been shown by cDNA arrays on cell lines of SCCL and MCC to be specific for SCCL. Eighty-three percent (49/59) of SCCL were positive for MASH1 and none (0/30) MCC expressed this marker. In comparison, 73% (43/59) SCCL expressed TTF-1 and 3% (1/30) MCC expressed TTF-1. 36 Antibodies directed against the MCV T-antigen may also prove useful in distinguishing MCC from metastatic SCCL. In a recent study, 17 cases of frozen tissue MCC were evaluated for the presence of the MCV by quantitative PCR, and 15 of the 17 cases were analyzed by IHC with CM2B4 (antibody directed against the antigenic epitope on the MCV T antigen). Fifteen of the 17 cases (88%) were positive for the MCV genome by quantitative PCR, and 10 of the 15 (67%) cases were positive by IHC for CM2B4. Twenty-six cases of primary SCCL were negative for CM2B4, and 21 of 26 tumors (76%) were positive for TTF-1. 27 With further studies evaluating the expression of CM2B4 in other tumors in the differential diagnosis of MCC, this marker may prove useful in distinguishing MCC from SCCL and other histologic mimics. Last, other IHC makers reported positive in MCC include CD117, 37 CD99, 38 TdT, 39 and p63; 40 which can become important in the histologic evaluation of poorly differentiated cutaneous malignancies.
CLINICAL AND HISTOLOGIC PREDICTORS OF PROGNOSIS
There is no clear consensus regarding the clinical and histologic parameters of MCC as it relates to prognosis. Attempting to determine which factors influence prognosis in MCC, various studies have evaluated numerous clinical and histologic features. Most recently, an analysis of data from the National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) Program showed that gender, tumor site, and tumor size correlated with survival. Women with MCC (N=1131) had a greater relative survival rate than men (N=1642), with survival at 10 years of 64.8% and 50.5%, respectively. This gender-based difference in survival was statistically significant. Of interest, there was no significant age-specific difference in survival with an overall 10-year survival rate of 57.3%. Patients with tumors presenting in the upper extremities had the best prognosis (10 y survival of 60.7%), followed by head/neck (57.1%), lower extremities (56.7%), and trunk (53.7%). The survival rates between patients with lesions of the head versus upper extremities and patients with trunk versus both upper and lower extremities lesions were statistically significant. The 10-year survival rate for tumors less than or equal to 2 cm in diameter was 61%, whereas tumors greater than 2 cm was 39.6%; this difference in survival was also statistically significant. 23 Tumor thickness has been reported not to be an independent predictor of disease-free or overall survival in patients with MCC, even though mean tumor thickness increased with tumor stage. 41 In contrast, in a study of 156 patients with MCC, Andea et al 42 reported that tumor size, thickness, and anatomic depth of invasion correlated with a decreased survival. Similarly, Llombart et al 43 reported an association between tumors greater than 10 mm in thickness and higher rates of distant metastasis, but survival was not evaluated. Depth of invasion has also been shown to be a strong predictor of outcome. In a study of 25 cases of MCC, 78% of tumors which extended beyond the dermis metastasized, whereas dermally confined tumors metastasized in only 29% of cases. 44 Despite the debate, evidence is mounting correlating prognosis to tumor thickness and depth of invasion, warranting the examination of these parameters.
On the basis of a review of the SEER data, the single best predictor of survival was stage of disease. 23 Until recently, one of the most commonly used staging systems was based on 4 tiers, taking into account tumor size, regional lymph node status, and distant metastasis. 45 This 4-tiered staging system incorporates tumor size; based on the findings of Allen et al 46 showing primary tumor size as an independent predictor of survival in patients with no evidence of clinical nodal disease. Most recently, the American Joint Commission on Cancer release in 2009 a new consensus staging system for MCC. In this staging system, MCC can be classified into 1 of 5 possible stages (0-IV), with possible substages (A, B, or C). Substage A designates pathologically proven node negative disease, substage B indicates nodes evaluated clinically, whereas stage II has the additional substage C for tumors with extracutaneous involvement and negative nodal status either by clinical or histologic examination. In cases of MCC with no evidence of nodal or metastatic disease (Stage I or II), the stage is determined by tumor size (Stage I: primary tumor r2 cm in diameter and Stage II: primary tumor greater than 2 cm in diameter). In this staging system, primary tumor (T) includes the designations Tis for an in situ tumor. The staging system also takes into account regional lymph nodes (N) and distant metastasis (M). In addition, a list of prognostic factors was recommended for collection: measured tumor thickness, tumor base transection status, profound immune suppression, tumor infiltrating lymphocytes in the primary tumor, growth pattern, size of the tumor nests in regional lymph nodes, clinical status of regional lymph nodes, reporting of regional lymph node extracapsular extension, and isolated tumor cells in regional lymph nodes. Of note, none of the latter prognostic factors or histologic grade is used in the staging of MCC. 47 Several histologic parameters have been evaluated in an attempt to prognostically stratify patients with MCC. Such histologic features include mitotic rate, cell size, growth pattern, lymphocytic infiltrate, angiolymphoid invasion, vascular density, and mast cell infiltrate. Skelton et al 10 reviewed at total of 132 cases of MCC, and only those patients who died of tumor or were alive with tumor (97 patients) were evaluated for features that correlated with survival. Features that predicted a decreased survival included small cell size (approximately twice the size of mature lymphocytes) and a high mitotic rate (more than 10 mitoses per 40 Â field). Similarly, Llombart et al 43 reported a significant association between a mitotic index greater than 10 mitoses per high-power field and tumor size greater than 30 mm. Related to mitotic index, an increased Ki67 of more than 50% by IHC was associated with a poor prognosis in the same study. Along with these findings, it was also shown that cell size (small, intermediate, or large) and histologic pattern had no prognostic significance. Therefore, tumor size and an increased mitotic rate are frequently reported, but less emphasis is placed upon cell size as it relates to prognosis.
By univariate and multivariate analysis of 156 cases of MCC, an improved survival was observed in patients with a nodular growth pattern. 42 Along the same lines, Mott et al 44 reported poor outcomes in patients with tumors showing a diffuse growth pattern. With regard to lymphocytic infiltration, there are conflicting results. In the study by Mott et al, 44 a poor prognosis was associated with the presence of a heavy lymphocytic infiltrate, whereas Llombart et al 43 reported the absence of an inflammatory infiltrate as a poor prognostic factor. Further studies are needed in this area to determine the prognostic importance of tumoral inflammation. Less conflicting evidence is associated with the presence of lymphovascular invasion, which is thought to portend a poor prognosis. [42] [43] Most recently, it has been reported that increased mast cell density (tryptase IHC) 48 and increased vascular density (CD34 IHC) 49 are associated with an adverse prognosis.
The argument can be made that the most important histologic features which should be reported include: tumor size, depth of invasion, anatomic depth of involvement, mitotic count, histologic growth pattern, and lymphovascular invasion. Other features such as tumor lymphocytic infiltration and tumor cell size can be reported as additional information but their significance is debated. With further studies, features such as vascular density and mast cell infiltrate may prove essential in the reporting of MCC.
IMMUNOHISTOCHEMICAL

PREDICTORS OF PROGNOSIS
Immunohistochemically, p63 expression in MCC has been associated with a more aggressive clinical course. In a series of 47 cases of MCC, 25 tumors expressed p63 (>10% positive cells), showing p63 as an independent predictor of poor prognosis. Interestingly, p63 expression did not correlate with tumor location, size, stage, sex, age, mitotic count, cell size, or angioinvasion. 40 IHC expression of survivin, an antiapoptotic protein, was evaluated in 19 cases of MCC, and nuclear subcellular localization of survivin correlated with a worse prognosis. In the same study, p63 and Ki67 expression were also carried out. Correlation was noted between p63 and nuclear survivin expression; both associated with a worse prognosis. Ki67 expression did not correlate with p63 or survivin expression and did not correlate with outcome. 50 Using a microarray, 31 cases of MCC were evaluated for IHC expression of 43 markers. A statistically significant correlation between metastatic tumor spread and overexpression was seen with these markers: matrix metalloproteinase 7, matrix metalloproteinase 10/2, tissue inhibitor of metalloproteinase 3, vascular endothelial growth factor (VEGF), P38, synaptophysin, and stromal NF-kB. As important, no prognostic association was found with Bcl-2, P53, or CD117 expression. In comparison with the aforementioned study evaluating survivin expression, all cases showed nuclear reactivity for survivin, which was independent of clinical outcome. 51 Currently, targeted anticancer therapies are used in specific tumor types. A recent study evaluated 32 MCC samples in an attempt to identify potential molecular targets. Using tissue microarray and IHC, these molecular targets were identified in MCC: VEGF-A (91%), VEGF-R2 (88%), Mcl-1 (88%), Bmi-1 (78%), VEFGF-C (75%), PDGF-a (72%), PDGF-b (13%), and CD117 (7%). All cases showed no expression of epidermal growth factor receptor and Her-2/Neu, with no CD117 mutations identified. 52 Further studies are needed to evaluate mRNA expression of these potential therapeutic targets in MCC to determine the use of anticancer therapies.
SENTINEL LYMPH NODE BIOPSY
The role of lymphoscintigraphy and sentinel lymph node biopsy (SLNB) in the management of MCC remains controversial. Until recently, MCC was classified based on a 4 tiered system; stage I (local disease with the primary tumor less than 2 cm in diameter), stage II (local disease with the primary tumor greater than or equal to 2 cm), stage III (nodal disease), and stage IV (metastatic disease). 45 Several studies have reported rates of positive SLNB or elective lymph node dissections ranging from 25%-30% in patients with clinical stage I disease. Interestingly, the incidence of clinically occult nodal disease was not associated with tumor size. These studies have also reported high rates of disease relapse, and the extent of disease in the nodal basin was associated with a decreased 5-year survival rate. 45 In a group of 77 patients with positive lymph nodes, those with 1 positive node (n=40), the 5-year survival rate was 66%; patients with 2 to 4 positive nodes (n=21), the 5year survival was 62%; and those with more than 4 positive nodes (n=16), the 5-year survival rate was 30%. 45 In addition to these findings, CT imaging of asymptomatic patients with stage I disease has been shown to lack sensitivity and leads to a large number of false positive results. 53 Proponents of SLNB in MCC report that pathologic nodal evaluation prevents under staging, gives a more accurate representation of stage-specific survival, identifies patients with a better long-term survival, and decreases regional nodal recurrence rates. In a recent study of 213 patients who underwent regional lymph node evaluation, it was shown that patients with tumors less than or equal to 1 cm in diameter were unlikely to have regional lymph node metastasis, precluding the need for SLNB in this group. Only 4% (2/54) of patients with tumors less than or equal to 1 cm had pathologic evidence of nodal disease, whereas 22% of patients with tumors 1 to 2 cm, and 41% of patients with tumors greater than 2 cm had evidence of nodal disease. 54 At the same time, no survival benefit of SLNB and regional lymph node dissection has been shown in patients with MCC. Further studies are needed evaluating the survival benefit of SLNB and dissection in patients with MCC. Ultimately, SLNB may play a role in stratifying patients for therapeutic reasons.
TREATMENT
There is agreement that the primary treatment of MCC is surgical excision with negative margins obtained whenever possible. Debate does exist concerning the size of the margins needed to treat. Traditionally, wide local excision with margins of 2 to 3 cm was recommended. A statistically significant difference in locoregional relapse (27% vs 89%, P<0.01) and 2-year survival (86% vs 28%, P<0.03) was reported with patients treated with wide local excision of 2.5 cm or greater compared with those with simple excision. 55 More recent studies have shown low (8%) recurrence rates with margin-negative excisions with margins averaging 1 cm. A decrease in local recurrence was not associated with obtaining a surgical margin of more than 1 cm. 45 In a study of 66 patients with MCC in the head and neck region, locoregional recurrence and survival did not change significantly when margins of 1 cm, 1 to 2 cm, and more than 2 cm were compared. 56 Controlled trials comparing outcomes with different margins of excision are needed to assist in establishing more uniform treatment recommendations.
Last, the role of adjuvant radiotherapy in MCC is also a debated topic. In a recent analysis of SEER data, an increase in overall survival was shown in patients treated with surgery plus radiation compared with patients treated with surgery alone. Patients that received adjuvant radiation therapy (n=477) had a median survival of 63 months, compared with a median survival of 45 months in the surgery alone group (n=689). Radiation therapy was also shown to improve survival in tumors of all sizes, but the greatest impact on survival was in cases with tumors greater than 2 cm. 23 Questions concerning the role for adjuvant radiotherapy in cases of regional lymph node involvement still require further evaluation. At this time, adjuvant chemotherapy is of little use because the majority of MCC do not respond to standard chemotherapeutic options. Specific chemotherapeutic agents may potentially prove useful in the future based on targeting of specific tumor antigens.
